+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hemochromatosis - Pipeline Review, H2 2019

  • ID: 4901330
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 45 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Bond Biosciences
  • Ionis Pharmaceuticals Inc
  • Panorama Research Inc
  • Silence Therapeutics Plc
  • Vifor Pharma AG
  • MORE
Hemochromatosis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hemochromatosis - Pipeline Review, H2 2019, provides an overview of the Hemochromatosis (Genetic Disorders) pipeline landscape.

Hemochromatosis is an iron disorder in which the body simply loads too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C and history of diabetes, heart disease, or liver disease.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively.

Hemochromatosis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemochromatosis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemochromatosis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemochromatosis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemochromatosis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemochromatosis (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemochromatosis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemochromatosis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bond Biosciences
  • Ionis Pharmaceuticals Inc
  • Panorama Research Inc
  • Silence Therapeutics Plc
  • Vifor Pharma AG
  • MORE
Introduction
Report Coverage
Hemochromatosis - Overview
Hemochromatosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hemochromatosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hemochromatosis - Companies Involved in Therapeutics Development
Bond Biosciences
Ionis Pharmaceuticals Inc
La Jolla Pharmaceutical Company
Panorama Research Inc
Protagonist Therapeutics Inc
Silence Therapeutics Plc
Vifor Pharma AG
Hemochromatosis - Drug Profiles
Hemochromatosis - Dormant Projects
Hemochromatosis - Discontinued Products
Hemochromatosis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Hemochromatosis, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hemochromatosis - Pipeline by Bond Biosciences, H2 2019
Hemochromatosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Hemochromatosis - Pipeline by La Jolla Pharmaceutical Company, H2 2019
Hemochromatosis - Pipeline by Panorama Research Inc, H2 2019
Hemochromatosis - Pipeline by Protagonist Therapeutics Inc, H2 2019
Hemochromatosis - Pipeline by Silence Therapeutics Plc, H2 2019
Hemochromatosis - Pipeline by Vifor Pharma AG, H2 2019
Hemochromatosis - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Hemochromatosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bond Biosciences
  • Ionis Pharmaceuticals Inc
  • La Jolla Pharmaceutical Company
  • Panorama Research Inc
  • Protagonist Therapeutics Inc
  • Silence Therapeutics Plc
  • Vifor Pharma AG
Note: Product cover images may vary from those shown
Adroll
adroll